Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of “Buy” by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have been given an average rating of “Buy” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.80.

ACHV has been the topic of several research analyst reports. RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a “strong-buy” rating in a research report on Thursday, November 14th. Raymond James started coverage on Achieve Life Sciences in a research report on Friday, September 27th. They set a “strong-buy” rating and a $20.00 price target on the stock. Finally, Rodman & Renshaw started coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $12.00 price objective for the company.

Institutional Trading of Achieve Life Sciences

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock worth $3,552,000 after purchasing an additional 48,474 shares in the last quarter. State Street Corp raised its position in shares of Achieve Life Sciences by 6.8% in the third quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 27,419 shares during the period. Barclays PLC grew its stake in shares of Achieve Life Sciences by 303.1% in the third quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 35,832 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Achieve Life Sciences by 134.2% during the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 14,360 shares during the period. Finally, MetLife Investment Management LLC raised its stake in shares of Achieve Life Sciences by 65.6% in the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares in the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Stock Down 4.0 %

Shares of Achieve Life Sciences stock opened at $3.38 on Friday. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. Achieve Life Sciences has a 12-month low of $3.37 and a 12-month high of $5.59. The firm has a market capitalization of $116.24 million, a PE ratio of -2.99 and a beta of 1.66. The stock’s fifty day moving average is $4.20 and its 200-day moving average is $4.50.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.10). During the same quarter in the prior year, the firm earned ($0.34) EPS. Equities analysts anticipate that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.